OpenAI safety leader David Robinson resigns as the team's upheaval mounts57m ago Apple to Tighten Mac Data Controls in Guard Against AI Agents1h ago Contest-Winning Microscope Video Is Full of AI Confabulations, Scientists Say1h ago The Mulleted, Meme-Loving Billionaire Behind Meta’s Hit AI App1h ago What is recursive self-improvement and what would it mean to ban it?2h ago Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration2h ago State of the Field: AI for Epistemics and Coordination2h ago The Netherlands considers banning Meta AI glasses as some retailers pull them from shelves2h ago AI can’t fix a business system with broken processes2h ago How to apply to AI safety fellowships (and beyond)2h ago Anthropic funds $100M academy to train deployed AI engineers2h ago Decagon Joins OpenAI’s B2B Marketplace as a Launch Partner3h ago Humanoid Robots Are Leaving Safety Cages. Proving Actual Safety Is Harder3h ago Meta open sources code to let you make Muse AI gadgets3h ago

OpenAI safety leader David Robinson resigns as the team's upheaval mounts57m ago Apple to Tighten Mac Data Controls in Guard Against AI Agents1h ago Contest-Winning Microscope Video Is Full of AI Confabulations, Scientists Say1h ago The Mulleted, Meme-Loving Billionaire Behind Meta’s Hit AI App1h ago What is recursive self-improvement and what would it mean to ban it?2h ago Cerebras stock hits post-IPO low, tumbling 20% for the week on Nvidia pressure and lockup expiration2h ago State of the Field: AI for Epistemics and Coordination2h ago The Netherlands considers banning Meta AI glasses as some retailers pull them from shelves2h ago AI can’t fix a business system with broken processes2h ago How to apply to AI safety fellowships (and beyond)2h ago Anthropic funds $100M academy to train deployed AI engineers2h ago Decagon Joins OpenAI’s B2B Marketplace as a Launch Partner3h ago Humanoid Robots Are Leaving Safety Cages. Proving Actual Safety Is Harder3h ago Meta open sources code to let you make Muse AI gadgets3h ago

OpenEvidence Confirms It Has Raised An Additional $250 Million At A $15 Billion Valuation

ForbesPublished 2 days ago

Read the full article

OpenEvidence, an AI-powered clinical decision support tool, has secured an additional $250 million in funding, reaching a valuation of $15 billion. This investment underscores the growing financial interest in AI applications within healthcare.

More on this story

The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round
8d· Business Insider

#clinical-decision-support #openevidence

More in Healthcare

Healthcare6 min read

How AI Assistants Get Paid Will Decide Whether They Help Or Harm Patients

Forbes11h ago

Healthcare5 min read

The AI Chatbots That Tech Companies Are Aggressively Pushing to Billions of Users Appear to Be Causing Serious Psychological Harms, New Research Finds

Futurism11h ago

The Quest to Quiet Hospital Alarms

The Wall Street Journal8h ago